Raloxifene hydrochloride

Grouped product items
Size	Price	Qty
50mg	$35.00
250mg	$145.00

Catalog Number : 8260480

description

Raloxifene is a selective estrogen receptor modulator that tissue-dependently either activates or blocks estrogen-induced transcription. It acts as an estrogen agonist in bone tissue and as an antiestrogen in breast or uterine tissue. Raloxifene is reported to enhance osteoblast differentiation and protects endothelial cells against oxidative stress.

Additional Information

Applications:	FA
Synonyms:	Evista, Keoxifene, LY 156758, LY156758
Formulation:	Crystalline solid
Chemical Name:	[6-hydroxy-2-(4-hydroxyphenyl)-1-benzothiophen-3-yl]-[4-(2-piperidin-1-ylethoxy)phenyl]methanone;hydrochloride
Molecular Formula:	C₂₈H₂₇NO₄S HCl
Molecular Weight:	510.2
CAS Number	82640-04-8
Purity:	≥98%
Storage Conditions:	Product should be kept at -20°C.
References:	Delmas, P. D., Bjarnason, N. H., Mitlak, B. H., Ravoux, A. C., Shah, A. S., Huster, W. J., ... & Christiansen, C. (1997). Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women. New England Journal of Medicine, 337(23), 1641-1647. Black, L. J., Sato, M., Rowley, E. R., Magee, D. E., Bekele, A., Williams, D. C., ... & Bensch, W. R. (1994). Raloxifene (LY139481 HCI) prevents bone loss and reduces serum cholesterol without causing uterine hypertrophy in ovariectomized rats. Journal of Clinical Investigation, 93(1), 63. Taranta, A., Brama, M., Teti, A., Scandurra, R., Spera, G., Agnusdei, D., ... & Migliaccio, S. (2002). The selective estrogen receptor modulator raloxifene regulates osteoclast and osteoblast activity in vitro. Bone, 30(2), 368-376.